Hormone-refractory prostate cancer is a disease that is incurable by current standard treatments. Research points to Immunotherapy as a possible recourse in this regard.
For hormone-refractory patients, as well as for prostate cancer patients at any stage, we provide a vaccine which represents an autologous cellular immunotherapy.
It can be classified as an active specific cancer immunotherapy, which is designed to stimulate a patient’s immune system to target prostate cancer cells. The preparation of the vaccine involves culturing the patient’s peripheral monocytes and dendritic cells in vitro in the presence of a recombinant growth factor, GM-CSF, special cytokines and their own prostate-specific antigen, which is fractionated into peptides in order to achieve an even more specific immune response.
Dendritic cells (DC) are highly specialized antigen-presenting cells and play a key role in the immunological reactions throughout the body.
Doses and interval depend on the patient’s response and general condition. The side effects that some patients may experience comprise flu-like symptoms, a rise of body temperature for several hours and pain or tenderness in the tumor area for several days.
Sam S Chang, MD, FACS, Rev. Urol. 2007; 9(Suppl 2): S13–S18. PMCID: PMC1887817. “Treatment Options for Hormone-Refractory Prostate Cancer”